Evaluation of Cobas b 101 HbA1c Analyzer Performance for Point-of-Care Testing
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The use of point-of-care (POC) devices for evaluating HbA1c is increasing; accordingly, comparisons between these devices and central laboratory methods are important. In the present study, we evaluated the analytical performance of the cobas b 101 analyzer for POC HbA1c testing. Methods: The analytical quality of the cobas b 101 system was assessed based on repeatability, within-laboratory precision, linearity, and lot-to-lot reproducibility. Two specimen types, i.e., EDTA whole blood and capillary blood, were examined using the cobas b 101 system and the Variant II Turbo instrument. Results: The coefficient of variation for within laboratory precision was 5.22% for a normal HbA1c level and 2.56% for a higher HbA1c level. The method showed good linearity, with a coefficient of correlation of 0.990. In a comparison of two different HbA1c disk lots, a strong correlation (r=0.986) and a mean %difference of -2.9% were observed. The cobas b 101 results using EDTA whole blood were strongly correlated with the Variant II Turbo results (r=0.958), with a mean %difference of 0.8%; the cobas b 101 results using capillary blood were strongly correlated with the Variant II Turbo results, using EDTA whole blood (r=0.976), with a mean %difference of 2.0%. A comparison between HbA1c levels in EDTA whole blood and capillary blood obtained using the cobas b 101 showed a strong correlation (r=0.985) and a mean %difference of 1.3%. Conclusions: The cobas b 101 analyzer is convenient for the measurement of HbA1c levels for diabetes management.
Abstract
Background: The use of point-of-care (POC) devices for evaluating HbA1c is increasing; accordingly, comparisons between these devices and central laboratory methods are important. In the present study, we evaluated the analytical performance of the cobas b 101 analyzer for POC HbA1c testing. Methods: The analytical quality of the cobas b 101 system was assessed based on repeatability, within-laboratory precision, linearity, and lot-to-lot reproducibility. Two specimen types, i.e., EDTA whole blood and capillary blood, were examined using the cobas b 101 system and the Variant II Turbo instrument. Results: The coefficient of variation for within laboratory precision was 5.22% for a normal HbA1c level and 2.56% for a higher HbA1c level. The method showed good linearity, with a coefficient of correlation of 0.990. In a comparison of two different HbA1c disk lots, a strong correlation (r=0.986) and a mean %difference of -2.9% were observed. The cobas b 101 results using EDTA whole blood were strongly correlated with the Variant II Turbo results (r=0.958), with a mean %difference of 0.8%; the cobas b 101 results using capillary blood were strongly correlated with the Variant II Turbo results, using EDTA whole blood (r=0.976), with a mean %difference of 2.0%. A comparison between HbA1c levels in EDTA whole blood and capillary blood obtained using the cobas b 101 showed a strong correlation (r=0.985) and a mean %difference of 1.3%. Conclusions: The cobas b 101 analyzer is convenient for the measurement of HbA1c levels for diabetes management.
참고문헌 (27)
- Gonen B, "Haemoglobin A1 : An indicator of the metabolic control of diabetic patients", Lancet, 2, pp.734~737 (1977)
- Cas Weykamp, "HbA1c: A Review of Analytical and Clinical Aspects", Annals of Laboratory Medicine, 33(6), pp.393~400 (2013), 대한진단검사의학회
- Weykamp C, "A review of the challenge in measuring hemoglobin A1c", J Diabetes Sci Technol, 3, pp.439~445 (2009)
- Cagliero E, "Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients", Diabetes Care, 22, pp.1785~1789 (1999)
- Ferenczi A, "Effect of immediate hemoglobin A1c results on treatment decisions in of ce practice", Endocr Pract, 7, pp.85~88 (2001)
- Miller CD, "Rapid A1c availability improves clinical decision-making in an urban primary care clinic", Diabetes Care, 26, pp.1158~1163 (2003)
- International Expert Committee, "International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes", Diabetes Care, 32, pp.1327~1334 (2009)
- Diabetes Control, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
- UK Prospective Diabetes Study(UKPDS)Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33)", Lancet, 352, pp.837~853 (1998)
- Petersen JR, "Hemoglobin A1c : assessment of three POC analyzers relative to a central laboratory method", Clin Chim Acta, 411, pp.2062~2066 (2010)
- 이지은, "Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol", Annals of Pediatirc Endocrinology & Metabolism, 20(2), pp.74~78 (2015), 대한소아내분비학회
- Sanchez-Mora C, "Evaluation of two HbA1c point-of-care analyzers", Clin Chem Lab Med, 49, pp.653~657 (2011)
- Wan Mohd Zin RM, "Haemoglobin A1c : comparing performance of two point of care devices with laboratory analyser", BMC Res Notes, 6, pp.540~ (2013)
- Lenters-Westra E, "Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria", Clin Chem, 60, pp.1062~1072 (2014)
- Mayega RW, "Comparison of fasting plasma glucose and haemoglobin A1c point-of-care tests in screening for diabetes and abnormal glucose regulation in a rural low income setting", Diabetes Res Clin Pract, 104, pp.112~120 (2014)
- Brown M, "Does availability of expanded point-of-care services improve outcomes for rural diabetic patients?", Prim Care Diabetes, 7, pp.129~134 (2013)
- Clinical and Laboratory Standards Institute, "Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline. CLSI document EP05-A3" (2014), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Evaluation of Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. CLSI guideline EP06-A. Wayne" (2003), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline. CLSI document EP09-A3" (2013), Clinical and Laboratory Standards Institute
- World Health Organization, "Global report on diabetes" (2016), World Health Organization
- International Organization for Standardization, "ISO 15197: Determination of performance criteria for in vitro blood glucose monitoring systems for management of human diabetes mellitus", International Organization for Standardization, ~ (2002)
- Lenters-Westra E, "Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria", Clin Chem, 56, pp.44~52 (2010)
- "Harmonizing Hemoglobin A1c Testing"[URL]
- Little RR, "Status of hemoglobin A1c measurement and goals for improvement : from chaos to order for improving diabetes care", Clin Chem, 57, pp.205~214 (2011)
- "College of American Pathologists (CAP) GH5 Survey Data"[URL]
- Shephard MD, "Analytical goals for point-of-care testing used for diabetes management in Australian health care settings outside the laboratory", Point Care, 5, pp.177~185 (2006)
- American Diabetes Association, "6. Glycemic Targets", Diabetes Care, 40, pp.S48~S56 (2017)